GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Gilead is a biopharmaceutical company focused on anti-infectives. Key products include HIV treatments (Viread, Truvada, Emtriva), Hepatitis B treatment (Hepsera), and antifungal therapy (AmBisome). The company also earns royalties from Tamiflu (licensed to Roche) and Macugen (licensed to Eyetech).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 51% in Q3 2005 and 49% for the nine-month period compared to 2004. This was driven primarily by a 59% increase in HIV product sales, specifically the rapid uptake of Truvada.
• Profitability: Net income rose 58% in Q3 and 57% for the nine months ended September 30, 2005. Operating income increased significantly due to revenue growth outpacing expense increases.
• One-Time Cash Outflow: Operating cash flow for the nine months was impacted by a $341.3 million payment to Emory University to purchase royalty interests in emtricitabine (an active ingredient in HIV products).
• Expense Increases: R&D expenses rose 60% in Q3 and 36% for the nine months, driven by license fees (Japan Tobacco, Emory) and clinical development. SG&A expenses increased 37% in Q3, largely due to an $8.4 million charge for relocating European headquarters.

Guidance, Outlook, and Risks

Management Commentary and Guidance

• 2005 Revenue Outlook:
  • HIV Products: Expected to range between $1.365 billion and $1.385 billion.
  • AmBisome: Expected to range between $210 million and $220 million.
  • Hepsera: Expected to range between $170 million and $180 million.
• 2005 Expense Outlook:
  • R&D: Expected to range between $270 million and $280 million.
  • SG&A: Expected to range between $370 million and $380 million.
• Product Development: The company is evaluating new formulations for a fixed-dose combination of Truvada and Sustiva (BMS) after initial bioequivalence tests failed. The earliest potential U.S. NDA filing is the first half of 2006.

Risks and Contingencies

• Roche Dispute: Gilead delivered a notice of termination to Roche regarding the Tamiflu license agreement due to alleged material breaches, including royalty underpayments. An audit identified a potential $18.2 million underpayment for 2001-2003. The matter is in confidential binding arbitration. Gilead recorded the $18.2 million advance payment from Roche as a liability pending resolution.
• Competition: Increased competition in the Hepatitis B market (BMS's Baraclude) and antifungal market (Merck, Pfizer) poses risks to pricing and volume.
• Regulatory and Safety: Risks include potential safety issues with long-term use of HIV products, regulatory delays for new formulations, and the possibility of compulsory licenses in developing countries (e.g., Brazil).
• Accounting Changes: The company expects to adopt SFAS 123R (Share-Based Payment) on January 1, 2006, which will likely have a material impact on the income statement and earnings per share.

Investor Verification Checklist

• Roche Arbitration Outcome: Verify the status and potential financial impact of the arbitration regarding Tamiflu royalties and the termination of the 1996 agreement.
• Truvada vs. Viread Mix: Monitor the rate of patient switching from Viread to Truvada and its impact on gross margins, as Truvada has a lower margin profile.
• Emory Royalty Amortization: Confirm the amortization schedule and impact of the $341.3 million Emory royalty buyout on future Cost of Goods Sold.
• European Pricing Pressure: Assess the impact of government pricing controls and reimbursement policies in Europe on AmBisome and Hepsera sales.
• Truvada/Sustiva Combination: Track the progress of clinical trials for the new bi-layer formulation of the Truvada/Sustiva combination pill.